Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4961408 | 0.98 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2PDPK1LMNAPDE10A | |
| SCHEMBL8603051 | 0.93 | HPRT1 (0.48) | ALDH1A1SMN1; SMN2PDPK1LMNAPDE10A | |
| SCHEMBL17281511 | 0.83 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2PDPK1LMNAPDE10A | |
| SCHEMBL6118333 | 0.80 | SMN1; SMN2 (0.59) | ALDH1A1SMN1; SMN2PDPK1LMNAPDE10A | |
| SCHEMBL11261102 | 0.79 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2PDPK1LMNAPDE10A | |
| SCHEMBL18100110 | 0.79 | XIAP (0.46) | ALDH1A1SMN1; SMN2LMNAXIAPMEN1 | |
| SCHEMBL2170681 | 0.78 | RAB9A (0.53) | ALDH1A1SMN1; SMN2LMNAXIAPTDP1 | |
| SCHEMBL29843187 | 0.78 | RAB9A (0.53) | ALDH1A1SMN1; SMN2LMNAXIAPTDP1 | |
| SCHEMBL22457218 | 0.78 | XIAP (0.48) | ALDH1A1SMN1; SMN2PDPK1LMNAXIAP | |
| SCHEMBL7905015 | 0.78 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2LMNAPDE10AXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629356-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | claimed |
| EP-3565586-B1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS INC (US) | 2025-10-08 | — | — | EP | claimed |
| US-20240216343-A1 | ENDOTHELIAL IK AND SK CHANNEL ACTIVATION TO TREAT PULMONARY HYPERTENSION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2024-07-04 | — | — | US | claimed |
| CN-111670247-B | Method for preparing cancer spheroids and method for selecting colorectal cancer patients | 京诊断株式会社 | 2024-01-05 | — | — | CN | claimed |
| US-20230210966-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | LION BIOTECHNOLOGIES, INC. | 2023-07-06 | — | — | US | claimed |
| EP-3565586-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | Iovance Biotherapeutics, Inc. (US) | 2019-11-13 | — | — | EP | claimed |
| WO-2018129336-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2018-07-12 | — | — | WO | claimed |
| US-20170299609-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS WITH SK CHANNEL ACTIVATORS | WRIGHT STATE UNIVERSITY (US) | 2017-10-19 | — | — | US | claimed |
| US-20120103545-A1 | LASER-MARKABLE SUBSTRATE, AND ASSOCIATED MANUFACTURING METHOD | ARJOWIGGINS SECURITY (FR) | 2012-05-03 | — | — | US | claimed |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | claimed |
| EP-0282971-B1 | Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents | WARNER LAMBERT CO (US) | 1994-12-28 | — | — | EP | claimed |
| EP-0282971-A2 | Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents | WARNER-LAMBERT COMPANY (US) | 1988-09-21 | — | — | EP | claimed |
| US-12629356-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4631503-A1 | AVL-292 OR MK-5108 FOR USE IN THE TREATMENT OF PDAC | Molius Saglik Teknolojileri Anonim Sirketi (TR) | 2025-10-15 | — | — | EP | disclosed |
| EP-3565586-B1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS INC (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12312333-B2 | SK channel positive allosteric modulators | CHAPMAN UNIVERSITY (US) | 2025-05-27 | — | — | US | disclosed |
| EP-0003141-B1 | PROCESS FOR THE PREPARATION OF 2-AMINO-ARYLENOTHIAZOLE COMPOUNDS AND THEIR RING N-SUBSTITUTED DERIVATIVES | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-07-14 | — | — | EP | disclosed |
| US-4252963-A | CYCLIZATION OF PHENYLTHIOUREAS WITH THIONYL CHLORIDE | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-02-24 | — | — | US | disclosed |
| EP-0003141-A2 | Process for the preparation of 2-amino-arylenothiazole compounds and their ring N-substituted derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-07-25 | — | — | EP | disclosed |
| US-4006127-A | Cationic diazacyanine dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210966-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | KCNN3, KCNK3, KCNA3 | ALDH1A1 2567/4885SMN1; SMN2 4083/4885PDPK1 1644/4885 |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, MOGAT2 | ALDH1A1 802/4885SMN1; SMN2 4749/4885PDPK1 662/4885 |
| US-12629356-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | PBK, IL2, KCNN3 | ALDH1A1 3306/4885SMN1; SMN2 3141/4885PDPK1 1593/4885 |
| US-12312333-B2 | SK channel positive allosteric modulators | KCNN1, KCNN4, KCNN2 | ALDH1A1 4418/4885SMN1; SMN2 1950/4885PDPK1 1550/4885 |
| US-20170299609-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS WITH SK CHANNEL ACTIVATORS | KCNN3, KCNN2, KCNN1 | ALDH1A1 4205/4885SMN1; SMN2 5/4885PDPK1 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.